US citizen tests positive for Ebola in DRC outbreak

American aid worker infected as DRC Ebola outbreak continues to spread

A United States citizen working for the humanitarian organisation Samaritan’s Purse has tested positive for Ebola in the Democratic Republic of the Congo, the New York Times reported on 11 July 2026. The American is the second US citizen to be infected in the current outbreak, which the World Health Organization (WHO) determined to be a public health emergency of international concern (PHEIC) on 17 May 2026. The Times did not publish the worker’s name, age or current clinical condition, and Samaritan’s Purse had not been quoted in the cited excerpt at the time of writing.

The DRC’s latest Ebola outbreak is centred on the eastern Ituri region, where the WHO says two experimental drugs are now being trialled in what scientists have described as a record pace for setting up clinical research of this kind. According to the Guardian, the first patients were enrolled in the treatment trial just six weeks after the WHO’s PHEIC declaration. The Guardian’s reporting, dated 12 July 2026, did not name the two candidate therapies or the institutions sponsoring the trial, and it did not confirm whether the infected US citizen is among those enrolled.

Where the reporting stands

Only two of the provided sources directly address the infection of the American. The Times frames the case as the second US citizen to fall ill in the same outbreak, implying that an earlier US-linked infection has already been documented, but the cited excerpt does not detail that earlier case. The Guardian piece focuses on the clinical-trial architecture rather than the American patient, and provides no direct information about Samaritan’s Purse, the patient’s evacuation status, or US government involvement.

The remaining sources in the supplied material — covering the Guggenheim Museum’s legionnaires’ disease detection, the Trump administration’s birthright-citizenship politics, Kennedy Center renovation allegations, and Representative Ro Khanna being blocked by Israeli settlers in the West Bank — do not relate to the DRC Ebola story and have not been used in this article.

How we got here: the trajectory of the 2026 DRC outbreak

The current outbreak was declared a PHEIC by the WHO on 17 May 2026, an escalation that reflects the organisation’s assessment that the event poses a risk of cross-border spread and requires a coordinated international response. Ebola disease, caused by orthoebolaviruses, has produced repeated outbreaks in the DRC since the virus was first identified in 1976 near the Ebola River, and the country has been the epicentre of more declared outbreaks than any other.

The most severe prior episode, the 2018–2020 Kivu epidemic in eastern DRC, killed more than 2,200 people and was the second-largest Ebola outbreak in history, after the 2013–2016 West African epidemic that killed more than 11,000. Those episodes also drew in significant numbers of international aid workers, several of whom were infected and either evacuated for treatment abroad or died in the field. The pattern of expatriate and aid-worker infections is historically a marker of two things: the depth of exposure risk in field facilities, and the limitations of the protective equipment and protocols then in use.

Why it matters now

The infection of a Samaritan’s Purse worker matters for three concrete reasons. First, it is a direct signal that frontline responders — the people running case-identification, isolation, safe burials and now the clinical trial — remain exposed despite decades of improved protocols. Second, it raises the operational and political stakes for Western NGOs and their donors, who must decide whether to scale up, maintain, or temporarily pull staff from the affected zone. Samaritan’s Purse is a US-based evangelical humanitarian organisation that has historically been deeply involved in Ebola responses in West Africa and the DRC, and its workers have previously been among the highest-profile Western casualties of the disease. Third, the case will sharpen scrutiny of the two-drug trial now under way in Ituri: regulators, donors and the WHO will be watching whether experimental therapies can be delivered safely at trial sites that are simultaneously dealing with infections of their own staff.

The bigger picture: a faster trial, but no approved drug

The Guardian’s reporting makes clear that, as of mid-July 2026, there is still no approved drug for this outbreak. Two candidate therapies are being tested in Ituri, and the trial infrastructure was put in place and started enrolling patients within roughly six weeks of the WHO’s PHEIC declaration. The Guardian describes that timeline as a record pace for setting up and starting this kind of research, a benchmark worth keeping in historical perspective: during the 2018–2020 Kivu epidemic, the formal randomised evaluation of four therapeutics took months to negotiate and longer to scale, and only after the outbreak was already waning. The 2026 timeline suggests that the WHO, the DRC’s health authorities and their research partners have compressed the start-up phase substantially, but the Guardian’s excerpt does not provide enrolment numbers, site locations, or interim efficacy data, so it is not yet possible to say whether speed of set-up will translate into early, actionable results.

Where the reporting diverges or remains thin

The two directly relevant sources do not contradict each other, but they answer different questions. The Times is focused on the identity of the patient (US citizen, Samaritan’s Purse employee) and the count (the second American infected in this outbreak), while the Guardian is focused on the clinical research response. Neither source, in the supplied excerpts, addresses: the patient’s current clinical status; whether the worker has been evacuated to a higher-level treatment centre such as those run by Médecins Sans Frontières in Kinshasa or to a facility outside the DRC; whether the earlier US citizen infected in this outbreak survived; the precise strain of Ebola virus involved; the cumulative case and death toll of the current outbreak; or whether the infection of an aid worker has prompted any specific changes to the trial protocol or to NGO staffing levels in Ituri. These gaps are factual absences, not disagreements between sources, and they shape what can responsibly be said.

What to watch next

Several specific developments will move this story. The WHO publishes periodic situation updates on declared PHEICs; readers should watch for the next Disease Outbreak News release on the DRC outbreak, which will likely include updated case counts, geographic spread, and any mention of infections among health workers. Samaritan’s Purse and the US Embassy in Kinshasa are the two most plausible sources for an on-the-record statement on the worker’s condition and any planned evacuation. The clinical trial in Ituri will be the other live thread: enrolment numbers, the identity of the two drugs under study, and any interim safety signals will be early indicators of whether the fast set-up translates into usable evidence. Finally, the question of whether the second US-citizen infection prompts a coordinated US government response — through USAID, the US Centers for Disease Control and Prevention, or the State Department — is the political dimension to monitor in the days ahead.